GoodRx Prescription Savings Platform Shows Traction but Questions Linger on Healthcare Monetization
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
GoodRx typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$0.01 (+0.39%) | $0.12 (4.68%) | +$0.27 (+10.51%) | $0.37 (14.40%) |
| 2026-02-25 | +$0.08 (+3.38%) | $0.14 (5.88%) | -$0.46 (-18.78%) | $0.16 (6.53%) |
| 2025-11-04 | -$0.05 (-1.51%) | $0.12 (3.63%) | +$0.07 (+2.15%) | $0.25 (7.67%) |
| 2025-08-06 | -$0.05 (-1.14%) | $0.13 (2.85%) | -$0.87 (-20.05%) | $0.69 (16.01%) |
| 2025-05-07 | -$0.47 (-11.03%) | $0.70 (16.31%) | +$0.45 (+11.87%) | $0.50 (13.06%) |
| 2025-02-27 | +$0.09 (+1.84%) | $0.63 (12.88%) | +$0.00 (+0.00%) | $0.36 (7.20%) |
| 2024-11-07 | -$1.07 (-17.51%) | $1.35 (22.09%) | -$0.15 (-2.98%) | $0.23 (4.56%) |
| 2024-08-08 | -$1.60 (-18.58%) | $1.16 (13.47%) | +$0.20 (+2.85%) | $0.57 (8.09%) |
| Avg Abs Move | 6.92% | 10.23% | 8.65% | 9.69% |
Historical price action around GoodRx earnings has been volatile and unpredictable, with an average absolute Day +1 move of 8.65% and Day 0 move of 6.92%. The most recent earnings cycle in May 2026 saw relatively muted Day 0 action with a 0.39% gain, but Day +1 delivered a strong 10.51% rally despite the company merely meeting estimates—suggesting investors were relieved by stabilization after prior disappointments.
The pattern shows extreme variability, with Day +1 moves ranging from a 20.05% plunge in August 2025 (following a miss) to an 11.87% surge in May 2025 (following a beat). The February 2026 earnings particularly stand out: a modest 3.38% Day 0 gain was followed by a brutal 18.78% Day +1 decline, demonstrating how quickly sentiment can shift when results disappoint. The average Day 0 range of 10.23% and Day +1 range of 9.69% underscore the stock's tendency for wide intraday swings during earnings periods, making it a high-risk, high-reward setup for traders.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 17) |
| Expected Move | $0.72 (21.63%) |
| Expected Range | $2.62 to $4.06 |
| Implied Volatility | 134.81% |
The options market is pricing an expected move of 21.63% (±$0.72) for the August 21 expiration, significantly higher than the stock's average historical Day +1 move of 8.65%. This elevated implied volatility of 134.81% suggests options traders are anticipating a more dramatic reaction than typical, possibly reflecting heightened uncertainty about whether management can reverse the recent trend of misses and declining revenue.
Part 3: What Analysts Are Saying
Analyst sentiment on GoodRx remains cautious, with a consensus rating of 3.38 (Hold) that has remained unchanged over the past month. The 16 analysts covering the stock are divided: 4 Strong Buys and 1 Moderate Buy are offset by 9 Holds, 1 Moderate Sell, and 1 Strong Sell. This distribution reflects skepticism about the company's near-term prospects despite some believers in the long-term story.
The average price target of $3.34 sits essentially flat with the current price of $3.33, implying virtually no upside from current levels. However, estimates range widely from a low of $2.25 to a high of $5.00, indicating significant disagreement among analysts about the company's trajectory. The lack of upside in the consensus target suggests most analysts are taking a wait-and-see approach, wanting evidence of stabilization before becoming more constructive.
The unchanged sentiment trend over the past month indicates analysts have not felt compelled to adjust their views ahead of this earnings release, despite the stock's recent technical strength. This stability in ratings—neither improving nor deteriorating—suggests the Street is withholding judgment until management demonstrates it can meet or exceed expectations and provide credible guidance for returning to growth.
Part 4: Technical Picture
GoodRx enters earnings with strong technical momentum, as the Barchart Technical Opinion shows an 88% Buy signal, unchanged from last week but significantly improved from the 56% Buy reading a month ago. The stock is trading at $3.33, positioned above all major moving averages: the 5-day ($3.19), 10-day ($3.09), 20-day ($3.06), 50-day ($2.90), 100-day ($2.60), and 200-day ($2.68). This alignment suggests a bullish trend structure with the stock in a clear uptrend across all timeframes.
Timeframe Analysis:
- Short-term (100% Buy): Maximum bullish signal indicates strong near-term momentum heading into the earnings release
- Medium-term (100% Buy): Equally strong reading confirms the uptrend is well-established beyond just recent sessions
- Long-term (50% Buy): Moderate buy signal shows improving but less decisive strength in the longer-term trend
Trend Characteristics: The combination of Good strength and Strongest direction indicates a robust uptrend environment with momentum accelerating into earnings.
The stock has rallied approximately 24% from its 200-day moving average of $2.68, representing a significant technical breakout. The 50-day moving average at $2.90 is trending well above the 200-day, confirming the intermediate-term uptrend remains intact. However, the recent rally has pushed the stock into potentially overbought territory, with the price now 4.6% above even the short-term 5-day moving average.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $3.19 | 50-Day MA | $2.90 |
| 10-Day MA | $3.09 | 100-Day MA | $2.60 |
| 20-Day MA | $3.06 | 200-Day MA | $2.68 |
Key resistance may emerge near the $3.50 level if the stock continues higher, while support appears solid at the 20-day moving average around $3.06. The technical setup is supportive heading into earnings, with the stock riding strong momentum across all timeframes, but the extended nature of the recent rally means a disappointment could trigger an outsized reversal. Conversely, any positive surprise could propel the stock toward the high-end analyst target of $5.00, given the strong technical foundation now in place.